We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Most Drug Sponsors Conducting Required Postmarket Trials
Most Drug Sponsors Conducting Required Postmarket Trials
November 10, 2010
After having to back down this summer from its attempt to remove Shire’s ProAmatine from the market after the company failed to conduct additional postmarket trials, the FDA reports that most sponsors’ required postmarket clinical trials are on schedule.